UEMS Medical Specialty

Metabolic & Endocrinology

Nutraceutical approaches to metabolic dysregulation: GLP-1 companion formulas, insulin sensitisers, thyroid support, adipokine modulation, and comprehensive metabolic syndrome management.

19

dossiers

Cellular Longevity & Senolytics

Clock Gene Expression (CLOCK/BMAL1) Impact on Pharmacokinetics: Implications for Chrononutrition and Chronopharmacology

Current pharmaceutical and nutritional guidelines often neglect circadian rhythmicity, leading to suboptimal therapeutic efficacy and unpredictable pharmacokinetic profiles for molecular interventions. Integrating clock gene biology into dosing regimens requires precise understanding of ADME variations.

Circadian Rhythm Chronobiology Pharmacokinetics Drug Metabolism

Post-GLP-1 Metabolic Optimization

Drug-Induced Nutrient Depletion (DIND): Molecular Mechanisms of Iatrogenic Deficiencies in Chronic Pharmacotherapy

Mitigating drug-induced nutrient depletion requires advanced CDMO solutions to formulate targeted nutritional support that is compatible with existing chronic pharmacotherapy and addresses diverse mechanistic pathways of depletion.

Drug-Related Side Effects and Adverse Reactions Nutritional Deficiency Hydroxymethylglutaryl-CoA Reductase Inhibitors Ubiquinone

Microvascular Hemodynamics & Endothelial Integrity

Modulation of the Endothelial Glycocalyx and Vitamin K2-Dependent MGP Carboxylation in the Prevention of Vascular Calcification

Developing bioavailable formulations of vitamin K2 (MK-7) and novel compounds to robustly enhance endothelial glycocalyx integrity and MGP carboxylation for the prevention or reversal of vascular calcification presents significant delivery and stability challenges.

Endothelial Glycocalyx Vitamin K 2 Matrix Gla Protein Vascular Calcification

Female Endocrine-Metabolic Crosstalk

Female Endocrine-Metabolic Axis: Inositols, Antioxidants, and Advanced Formulation Technologies for PCOS

Developing multi-component formulations for female endocrine-metabolic disorders like PCOS requires precise active ingredient ratios, enhanced bioavailability for poorly absorbed compounds, protection of sensitive molecules, and dosage forms that ensure patient compliance.

Polycystic Ovary Syndrome Inositol Myo-Inositol D-Chiro-Inositol

Female Endocrine-Metabolic Crosstalk

Female Endocrine-Metabolic Axis: Formulation Technologies for Inositols and Antioxidants

Formulating stable, bioavailable, and patient-compliant products with precise inositol isomer ratios and sensitive antioxidants for female endocrine-metabolic health presents challenges in ingredient stability, dissolution, and avoiding paradoxical clinical effects from incorrect dosages.

Polycystic Ovary Syndrome Inositols Myo-Inositol D-Chiro-Inositol

Post-GLP-1 Metabolic Optimization

Amino-Peptide Matrices for Lean Mass Preservation in GLP-1 Receptor Agonist-Induced Gastroparesis

GLP-1 RA-induced gastroparesis and retained gastric contents present a significant challenge for effective oral nutrition delivery and lean mass preservation during weight loss therapy, especially in at-risk populations.

Glucagon-Like Peptide-1 Receptor Agonists Body Mass, Lean Gastroparesis Peptides

Cellular Longevity & Senolytics

Immunometabolism, Active Resolution of Inflammation, and Specialized Pro-resolving Mediators (SPMs) from EPA/DHA

Current anti-inflammatory strategies often inhibit active resolution pathways, leading to chronic inflammation. Developing stable, bioavailable specialized pro-resolving mediators (SPMs) or modulators that enhance endogenous SPM biosynthesis without compromising resolution is a significant challenge.

Specialized Pro-Resolving Mediators Resolvins Protectins Lipoxins

Post-GLP-1 Metabolic Optimization

In Vivo Gene Editing via Lipid Nanoparticles: Base Editor Mechanisms and PCSK9 Targeting

Developing safe, durable, and highly targeted in vivo delivery systems for gene editing machinery (e.g., mRNA encoding base editors) to specific tissues like the liver via LNPs remains a significant challenge, requiring precise control over biodistribution and off-target effects.

Gene Editing Lipid Nanoparticles PCSK9 protein, human Hyperlipidemias

Cellular Longevity & Senolytics

Targeted Mitochondrial Medicine: Synergistic Modulation of AMPK and NAD⁺ Salvage Pathways for Cardiometabolic Health

The challenge lies in developing stable, bioavailable, and synergistically effective combination formulations of NAD⁺ precursors and AMPK modulators to precisely target cellular bioenergetic decline in age-related cardiometabolic conditions.

Nicotinamide Adenine Dinucleotide AMP-Activated Protein Kinases Sirtuin 1 Nicotinamide Mononucleotide

Post-GLP-1 Metabolic Optimization

Nutraceutical Toxicology and Herb-Drug Interactions (HDI/NDI): A Clinical Review of Six Critical Pharmacological Mechanisms

Developing safe and effective drug formulations requires comprehensive consideration of potential, often undisclosed, herb-drug interactions that can compromise efficacy or lead to life-threatening toxicities, especially with narrow therapeutic index compounds.

Drug Interactions Nutraceuticals Herb-Drug Interactions Cytochrome P-450 Enzyme System

Precision Microbiome & Gut-Brain Axis

Pharmacomicrobiomics: Gut Microbiota Modulation of Drug Efficacy and Nutraceutical Biotransformation

Integrating the profound and variable metabolic capacity of the gut microbiome into pharmaceutical development to ensure consistent drug efficacy and bioavailability across diverse patient populations is a significant hurdle.

Pharmacomicrobiomics Gut Microbiota Drug Metabolism Xenobiotics

Post-GLP-1 Metabolic Optimization

Triple Agonists and Next-Generation Oral GLP-1s: Advancements in Metabolic Disorder Therapeutics

Formulating complex multi-receptor agonists and high-potency oral GLP-1 peptides requires advanced delivery systems to ensure bioavailability, stability, and patient adherence while mitigating gastrointestinal side effects.

Glucagon-Like Peptide-1 Receptor Agonists Glucose-Dependent Insulinotropic Polypeptide Glucagon Receptor Obesity

Catecholamine Homeostasis & Executive Function

Clinical Nutrigenomics: One-Carbon Metabolism, MTHFR/COMT Polymorphisms, and Unmetabolized Folic Acid Toxicity

Developing stable, bioavailable dosage forms of 5-methyltetrahydrofolate (5-MTHF) that effectively bypass common one-carbon metabolism genetic polymorphisms (e.g., MTHFR, COMT) is critical to prevent unmetabolized folic acid (UMFA) toxicity and ensure optimal folate status. This requires precise formulation to overcome stability issues inherent to reduced folates while ensuring clinical efficacy across genetically diverse populations.

Folic Acid MTHFR Protein Catechol O-Methyltransferase 5-Methyltetrahydrofolate

Glycolysis-Restricted FSMP (Oncology Nutrition)

The Glucose Paradox in Oncology Nutrition: Metabolic Compatibility of Medical Foods

Formulating oncology-specific medical foods that balance caloric adequacy with metabolic compatibility is challenging, as standard high-glycemic carbohydrate profiles can inadvertently fuel tumor progression and worsen cachexia in vulnerable patients.

Insulin Resistance Neoplasms Medical Oncology Glycolysis

Female Endocrine-Metabolic Crosstalk

Household Xenoestrogens and Nutritional Interventions: A Translational Endocrine Defense Framework

Designing medical foods that mitigate the effects of chronic, low-dose exposure to diverse endocrine-disrupting chemical mixtures, while adhering to regulatory definitions and ensuring compatibility with polypharmacy risks.

Estrogens

Intracellular Defense & IV-Alternatives

Isomeric Stabilization in High-Moisture Matrices: Protecting Fixed-Ratio Inositol Formulations

Fixed-ratio solid formulations are prone to segregation during manufacturing, especially under moisture-driven property changes, causing dose uniformity and accuracy challenges.

Cerebral Bioenergetics & Neuro-Metabolic Rescue

Ketogenic Diet-Specified Interventions in Neurodegenerative Disease Mechanisms

Developing a formulation that achieves consistent and measurable ketosis while optimizing bioavailability and tolerability in neurodegenerative conditions is a key challenge.

Alzheimer Disease Parkinson Disease Neurodegenerative Diseases Neuroinflammation

Precision Microbiome & Gut-Brain Axis

Enteric Delivery of Butyrate: Overcoming Gastrointestinal Barriers for Vagal Activation

Free butyrate salts dissolve prematurely in the upper gastrointestinal tract, limiting their availability for distal gut signaling. Additionally, their pungent odor and taste present significant challenges for patient adherence in chronic applications.

Aging Serotonin Gastrointestinal Microbiome Fatty Acids, Volatile

Post-GLP-1 Metabolic Optimization

Semaglutide: Gastrointestinal Effects and Post-Discontinuation Weight Regain, 2026

Developing GLP-1 formulations that balance robust metabolic benefits with reduced gastrointestinal side effects and mitigate post-discontinuation weight regain remains a significant challenge. The interplay between appetite modulation, gastrointestinal motility, and adverse event profiles adds complexity to product optimization.

Dopamine Cardiovascular System Brain-Gut Axis Glucagon-Like Peptide 1

Custom Formulation Available

Need a Dossier Built Around Your Molecule?

Our R&D team will conduct a Paid Discovery Audit and build a proprietary clinical dossier for your specific active ingredient or therapeutic target. Full IP transfer included.